| Expression pattern: |
UP |
| Associated gene: |
HIF-1a, Ago2 |
| Associated microRNA: |
miR-373 |
| Biological function: |
circRNA-UBE2G1 facilitates progression in the LPS-induced OA cell model; circRNA-UBE2G1 inhibition increases LPS-treated C28/I2 cell viability and reduces apoptosis and pro-inflammatory cytokine expression. |
| Molecular mechanism: |
circRNA-UBE2G1 acts as a competing endogenous RNA by binding/sponging miR-373, thereby regulating HIF-1a expression in LPS-induced chondrocyte injury. |
| Biological pathway or process: |
ceRNA regulation (other); apoptosis (promotes); proliferation (inhibits); inflammation (promotes) |
| Detected method: |
Q
|
| Validation methods: |
RT-qPCR; Clinical Sample Validation; Bioinformatics Analysis; Nuclear-Cytoplasmic Fractionation; Luciferase Reporter Assay; RIP (RNA Immunoprecipitation); Transfection; CCK8; EdU Staining; Annexin V/PI Flow Cytometry; ELISA; Western Blot |
| Clinical significance: |
High circRNA-UBE2G1 expression was positively associated with modified Mankin scores in OA patients, and circRNA-UBE2G1 might be considered a promising therapeutic target for OA treatment. |
| Description: |
circRNA-UBE2G1 (hsa_circ_0008956) is up-regulated in OA tissues and LPS-treated human C28/I2 chondrocytes, and higher expression correlates with higher modified Mankin scores. Mechanistically, it mainly localizes to the cytoplasm and functions as a ceRNA for miR-373 to regulate HIF-1a, thereby promoting LPS-induced chondrocyte injury, apoptosis, and inflammatory cytokine expression. Its inhibition alleviates LPS-induced OA-like cellular injury, suggesting potential therapeutic value in OA. |
| Confidence score: |
0.7295 |